Loading...

ImmunoGen, Inc.

IMGNNASDAQ
Healthcare
Biotechnology
$31.23
$0.005(0.02%)

ImmunoGen, Inc. (IMGN) Company Profile & Overview

Explore ImmunoGen, Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

ImmunoGen, Inc. (IMGN) Company Profile & Overview

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

SectorHealthcare
IndustryBiotechnology
CEOMark Joseph Enyedy

Contact Information

781 895 0600
830 Winter Street, Waltham, MA, 02451-1477

Company Facts

277 Employees
IPO DateNov 17, 1989
CountryUS

Frequently Asked Questions

;